Semaglutide can lead to weight loss, but which product is approved for it matters. Wegovy (a weekly injection, and a daily tablet) is the semaglutide medicine approved by the FDA for weight management. Ozempic and Rybelsus contain the same ingredient and are approved for type 2 diabetes. In the Wegovy label’s main 68-week trial, people on the 2.4 mg injection lost 14.9% of body weight on average versus 2.4% on placebo, alongside diet and activity (Wegovy prescribing information, section 14.2).
Which semaglutide product is for what
| Brand | Form | Approved use (adults unless noted) | Schedule | Maker |
|---|---|---|---|---|
| Ozempic | Injection | Type 2 diabetes: blood sugar control; lower cardiovascular and kidney risk in people with those conditions | Weekly | Novo Nordisk |
| Wegovy | Injection | Weight reduction and maintenance (also ages 12+ with obesity); cardiovascular risk reduction; MASH with liver fibrosis | Weekly | Novo Nordisk |
| Wegovy | Tablet | Weight reduction; cardiovascular risk reduction | Daily | Novo Nordisk |
| Rybelsus | Tablet | Type 2 diabetes: blood sugar control; cardiovascular risk reduction | Daily | Novo Nordisk |
Sources: Ozempic, Wegovy and Rybelsus prescribing information, section 1 of each. Details on the injection pair are in Ozempic vs Wegovy: key differences. In the US, Rybelsus is being replaced by Ozempic tablets (1.5 mg, 4 mg and 9 mg), the same daily semaglutide under a new name; they share one label and are not interchangeable mg for mg (Novo Nordisk).
How semaglutide works
GLP-1 is a hormone released after eating that supports insulin release, slows stomach emptying and acts on appetite regions of the brain. Semaglutide is a GLP-1 receptor agonist, a longer-acting copy of that signal. People often describe feeling full sooner, which is one reason weight can fall, but the response differs from person to person.
What the label’s trials show
The Wegovy label reports 68-week trials in which people also received diet and activity counseling. Average body weight change (Table 8) was:
- Adults with obesity or overweight and a comorbidity, 2.4 mg weekly: -14.9% vs -2.4% on placebo
- Adults with type 2 diabetes and obesity or overweight: -9.6% vs -3.4%
For the daily Wegovy 25 mg tablet, a 64-week trial showed -13.6% vs -2.4% on placebo (Table 11). The tablet’s own trial is also published (OASIS 4, NEJM 2025). These are averages from controlled trials, not promises: some people lose more, some less, and weight tends to return if treatment stops. For a time-based view, see how long Ozempic takes to work.
Dosing basics
Doses rise slowly to limit stomach side effects. Your prescriber sets the plan.
| Wegovy injection week | Weekly dose |
|---|---|
| 1 to 4 | 0.25 mg |
| 5 to 8 | 0.5 mg |
| 9 to 12 | 1 mg |
| 13 to 16 | 1.7 mg |
| 17 onward | 1.7 mg or 2.4 mg (2.4 mg recommended) |
Source: Wegovy prescribing information, section 2.2. The label also describes an increase to a maximum of 7.2 mg weekly for adults who tolerate 2.4 mg for at least 4 weeks and need additional weight reduction. The Wegovy tablet starts at 1.5 mg daily and steps up every 30 days (4 mg, 9 mg) to 25 mg daily. Ozempic starts at 0.25 mg weekly for 4 weeks, then 0.5 mg, with 1 mg and 2 mg available if more blood sugar control is needed.
If you miss a dose
Rules depend on the product, so check your own label and ask your pharmacist. For Wegovy injection: if the next scheduled dose is more than 2 days away, take the missed dose as soon as possible; if it is less than 2 days away, skip it. If 2 or more consecutive doses are missed, the label says treatment may need to restart at a lower dose. For Ozempic the label allows a missed dose within 5 days. For tablets (Wegovy, Rybelsus), skip the missed dose and take the next one the following day. Never double up.
Side effects
In Wegovy’s adult weight-loss trials, the most common reactions versus placebo (Table 3) were nausea (44% vs 16%), diarrhea (30% vs 16%), vomiting (24% vs 6%), constipation (24% vs 11%), abdominal pain (20% vs 10%) and headache (14% vs 10%). The label warns about thyroid C-cell tumors (a boxed warning based on rodent studies), pancreatitis, gallbladder disease, low blood sugar when combined with insulin or sulfonylureas, kidney injury from dehydration, an increased heart rate, diabetic retinopathy complications and allergic reactions. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Talk to your prescriber about symptoms that are severe or do not settle, such as persistent vomiting or intense abdominal pain, and do not change your dose yourself. See GLP-1 side effects: what to expect and how to manage them.
Safety: get it from a licensed source
The FDA states that unapproved versions of GLP-1 drugs do not go through its review for safety, effectiveness and quality, and advises buying prescription medicines only from state-licensed pharmacies. Warning signs include unrealistically deep discounts, no prescription from a licensed doctor, damaged packaging and spelling errors on labels (FDA: concerns with unapproved GLP-1 drugs). Semaglutide should be used under a prescriber’s supervision.
Tracking while on semaglutide
A log turns “I think it helps” into something you and your prescriber can review. Useful items: injection day, dose and site, side effects and their timing, meals and protein, water, and weekly weight. Protein and hydration are worth watching when appetite drops.
Mingo is a GLP-1 tracker for iPhone and Android that logs shots, food and protein, side effects and weight in one place. It doesn’t replace your doctor. Get the app, and see the GLP-1 weight loss medication guide for more on building a routine.
Key takeaways
- Wegovy is the semaglutide product approved for weight management; Ozempic and Rybelsus are approved for type 2 diabetes.
- In the Wegovy label’s 68-week trial, average weight change was -14.9% with 2.4 mg vs -2.4% with placebo, alongside lifestyle support.
- Doses start low and rise in steps; missed-dose rules differ between injection and tablet.
- Gastrointestinal effects are the most common side effects; report severe or lasting symptoms.
- Use only licensed pharmacies and a prescriber’s supervision.
Frequently asked questions
What is semaglutide used for?
It is the active ingredient in Ozempic and Rybelsus (type 2 diabetes) and in Wegovy (weight management and cardiovascular risk reduction, among other labeled uses). Which brand fits depends on your diagnosis and your prescriber’s judgment.
How does semaglutide help with weight loss?
It mimics GLP-1, which slows stomach emptying and acts on appetite signals so many people feel full sooner. In trials it was paired with diet and activity counseling.
What are common side effects of semaglutide?
Nausea, diarrhea, vomiting, constipation and abdominal pain are the most common. They are usually most noticeable as the dose is stepped up. Rarer serious risks include pancreatitis and gallbladder problems.
Is Ozempic the same as Wegovy?
Both are semaglutide injections but they are approved for different uses and use different dose ranges. Ozempic is for type 2 diabetes and Wegovy is for weight management.
Where can I get semaglutide prescribed?
From a licensed health care provider who can assess your health, and filled at a state-licensed pharmacy. Your own doctor, an obesity medicine clinic or a licensed telehealth provider may be options.
